skip to main content

GP2d

GP2d

Catalogue No.

95090714

Cell Line Name

GP2d

Cell Line Description

GP2d has been established from the same adenocarcinoma as GP5d (ECACC catalogue no. 95090715). This has been confirmed by STR profiling at ECACC. The cells were derived from a local recurrence of Duke's grade B, poorly differentiated carcinoma of the colon from a 71 year old female at surgical resection. The patient received no preoperative chemo- or radiotherapy and had a strong family history of colon cancer with two first degree relatives dying of the disease below the age of 55 years. Both clones possess genetic changes consistent with the pattern of tumour progression in colon cancer but are morphologically distinct. An interstitial deletion on chromosome 5 (region 14q to 22q) and an inverted duplication of bands 10q11 and 10q21 has been reported. Both cell lines contain a normal copy of the ki-ras gene and a copy with a transition in codon 12. GP2d cells show growth response to EGF, TGF alpha or insulin with an increase in cell numbers. Amphiregulin mRNA is abundant in GP2d but almost undetectable in GP5d.

Characteristics

Receptors

Epidermal growth factor (EGF)

Tissue of Origin

Colon

DNA profile (STR Profile)

Amelogenin: X
CSF1PO: 9,12
D5S818: 11,12
D7S820: 9,11
D13S317: 8,12
D16S539: 11,13
TH01: 7,9.3
TPOX: 8,11
vWA: 17,18

Karyotype

Diploid

Applications

Colon tumour assays, influence of growth factors and adhesion molecules on colonic tumour cells

Disease

Adenocarcinoma

Culture Conditions

Cell Type

Epithelial

Subculture Routine

Split sub-confluent cultures (70-80%) 1:3 to 1:6 i.e. seeding at 5x10,000 to 1x100,000 cells/cm² using 0.05% trypsin or trypsin/EDTA; 5% CO₂; 37°C.

Culture Medium

DMEM + 2mM Glutamine + 10% Foetal Bovine Serum (FBS).

Growth Mode

Adherent

Additional Info

Depositor

N Solic, Dr D E Davies, Dr J E Collins, CRC Wessex Medical Oncology Unit, University of Southampton

Country of Origin

United Kingdom

Hazard Group (ACDP)

Hazard Group (ACDP) 2

Applications

References

Solic N, Collins JE, Richter A, Holt SJ, Campbell I, Alexander P, Davies DE 1995 Two newly established cell lines derived from the same colonic adenocarcinoma exhibit differences in EGF-receptor ligand and adhesion molecule expression. Int J Cancer. 62(1):48-57 PMID: 7601566.

Bibliography

Barretina J, et al., 2012 The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature. 483(7391):603-7. PMID: 22460905.

Available Formats

  • Frozen
  • DNA-5µg (100ng/µl)

If use of this culture results in a scientific publication, it should be cited in the publication as: GP2d (ECACC 95090714).

Unless specified otherwise, at ECACC we routinely handle all of our cell lines at containment level 2 in accordance with the ACDP guidelines (Advisory Committee on Dangerous Pathogens) (UK). All cell cultures have the potential to carry as yet unidentified adventitious agents. It is the responsibility of the end user to ensure that their facilities comply with biosafety regulations for their own country. ACDP Guidance: Biological agents: Managing the risks in laboratories and healthcare premises.

The Culture Collections represent deposits of cultures from world-wide sources. While every effort is made to ensure details distributed by Culture Collections are accurate, Culture Collections cannot be held responsible for any inaccuracies in the data supplied. References where quoted are mainly attributed to the establishment of the cell culture and not for any specific property of the cell line, therefore further references should be obtained regarding cell culture characteristics. Passage numbers where given act only as a guide and Culture Collections does not guarantee the passage number stated will be the passage number received by the customer.

Cultures supplied by Culture Collections are for research purposes only. Enquiries regarding the commercial use of a cell line are referred to the depositor of the cell line. Some cell lines have additional special release conditions such as the requirement for a material transfer agreement to be completed by the potential recipient prior to the supply of the cell line. Please view the Terms & Conditions of Supply for more information.